One agent.
Real-world impact.

K Pro, the AI agent for biology, powered by multimodal patient data, for smarter biopharma decision making.

It continuously learns from real-world data, user feedback, and clinical validation. The first agent to connect research to care.

Gradient K Stripe

What can you do with K Pro?

Built for every step of your pipeline

From target discovery to portfolio strategy, ask questions in natural language and get rigorous, publication-ready answers from multimodal patient data.

Intelligent orchestration of specialized AI skills

K Pro uses a single intelligent orchestrator that dynamically selects and combines specialized AI skills to solve your challenges across drug discovery and development. Instead of juggling multiple tools, you work with one agent that knows exactly which capabilities to activate.

Book a Demo
AI connection Icon
Research-to-care intelligence
AI insights validated by real patients, connecting discovery to clinical reality
Multimodal Data Icon
Powered by multimodal patient data
From real multimodal patient data to real world impact
Secure Platform Icon
Secure, interpretable and interoperable platform
Deploy confidently: compliant, transparent, and built to connect
AI library Icon
A growing library of expert-grade AI skills
Validated, customizable AI skills built from a decade of biomedical research and world-class domain expertise
AI model Icon
Interoperable orchestration of expert AI model
One intelligent agent that knows which tools to activate at every step of discovery
Example Use Cases

Discover how K Pro powers smarter pipeline decisions

K Pro's flexible architecture means it can tackle your specific challenges, even ones we haven't anticipated yet.
Early Portfolio Decisions
Early Portfolio Decisions

Assess drug/program opportunities with confidence.

Patient & Population Decisions
Patient & Population Decisions

Define the right patient populations and predictive biomarkers before your trial starts.

Clinical Trial Decisions
Clinical Trial Decisions

Enrich early clinical trial data with real-world insights.

Features
FREE
Explore and demo on public data
Professional
+ K Pro Free
Decision-grade analysis on proprietary data
Data access
19 public datasets
MOSAIC subset (60 samples)
Plus:
Owkin proprietary datasets
Full MOSAIC spatial & multiomics dataset
Data upload
Cross
NO
Check
YES
Usage
Limited
High
Privacy
Logged activity
Untracked usage
Support
Standard
Dedicated onboarding & Account Manager
Deployment
SaaS access only
SaaS access or deployed on client premise/instance

Trusted by top biopharma and researchers

Dr. Ingo Ringshausen
“The potential impact for research teams is obvious, in particular thanks to its robust multi-omics patient data exploration capabilities.”
Dr. Ingo Ringshausen
Principal Investigator at University College London & Consultant Haematologist UCLH
Pr. Fabrice André
“Its ability to rapidly analyze and visualize complex patient data, including spatial omics, delivers insights in moments. It’s a game-changer.”
Pr. Fabrice André
Head of Research Division, Institut Gustave Roussy
Pr. Franck Bielle
“K has the potential to set new standards for efficiency in biomedical research, by streamlining complex data analysis.”
Pr. Franck Bielle
Neuropathologist at APHP, Head of Brain Tumor Heterogeneity Immunity & Therapy research team, Paris Brain Institute
Pr. Marc Sanson
"K makes complex data exploration effortless and enables researchers to efficiently generate new hypotheses."
Pr. Marc Sanson
Head of Neuro Oncology, APHP

Ready to get started?
Get in touch for a Demo

Discover how K Pro can transform your drug discovery and development. Connect with our team to explore how we can support your specific needs.

Book a Demo
K Pro FAQs
Questions?

Search for answers to our most commonly asked questions about K Pro.

Search FAQs
Button
*Certain potential users of Owkin K may be subject to anti-gift or anti-bribery regulations based on their profession and jurisdiction. Owkin is collecting all pertinent information from potential users to ensure that anti-gifting and bribery laws are followed across jurisdictions. Owkin reserves the right to restrict access to certain users who are prohibited from accepting them under applicable regulations.